Aram Hezel
The objective of this study is to investigate whether adding the study drug, NP137, to a patient's treatment regimen (before surgery and in combination with chemotherapy afterward) can alter the behavior of pancreatic cancer..
The aim of this study is to evaluate the mechanism of action for a novel anti-Netrin-1 antibody (NP137) in patients with pancreatic ductal adenocarcinoma. Pre-clinical data indicates that anti-Netrin-1 therapy can prevent/delay metastatic progression of disease by inducing cancer cell death through its dependence receptor Unc5b as well as prevent epithelial to mesenchymal transition (EMT). This pilot study is designed to provide vital translational scientific information that will inform the design of future clinical trials for NP137. This information includes determining the optimal use of N…
Inclusion Criteria: * Subjects with imaging suggesting resectable pancreatic cancer and without strong evidence of metastatic disease. * Accept to undergo biopsy for initial diagnosis and research purposes. NOTE: For patients who already have cytologically or histologically confirmed resectable pancreatic ductal adenocarcinoma, they must agree to undergo research biopsy. * Cytologically or histologically confirmed resectable pancreatic ductal adenocarcinoma. * Confirmed resectable pancreatic ductal adenocarcinoma by treating surgeon. * No prior systemic therapy, radiation therapy, or resectio…
NP137 for the Treatment of Resectable Pancreatic Cancer
Arctuva estimate
Verify or correct the compensation shown for this listing.